Royalty Pharma plc research snapshot
RPRX AI stock analysis reads Royalty Pharma as a buyer of biopharmaceutical royalties and a funder of innovation rather than a conventional drug developer. At the August 2, 2026 data cutoff, the latest verified static quote was $58.43 from the July 31 close, with a $33.65 billion market capitalization. First-quarter 2026 Portfolio Receipts rose 10% to $925 million and full-year guidance was raised to $3,325 million to $3,450 million, but the case still depends on drug life cycles, concentrated royalty assets, acquisition discipline, and roughly $9.2 billion of debt. Q2 2026 results are scheduled for August 5, 2026, after this cutoff. This page is informational only and not investment advice.
Current price
$58.43
Market cap
$33.65 billion
AI score
69 / 100
Rating
Cash-generative royalty platform with asset-life and leverage risk
Trend status
Uptrend above major moving averages, with momentum positive but no longer extended
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Royalty Pharma finances life-science innovation and receives contractual royalty cash flows from marketed therapies and development-stage assets. The model can produce cash without operating a global drug-sales force. | High |
| Moat | The moat is a long operating history, specialist underwriting, access to sellers, scale in complex royalty transactions, and a diversified portfolio. It is weaker if capital becomes abundant or deal pricing rises. | Medium-high |
| Management | Founder, CEO, and chairman Pablo Legorreta has led the platform since 1996. The key test is whether management can keep buying durable cash flows without overpaying while balancing debt, dividends, and buybacks. | Medium-high |
| Financial trend | FY2025 revenue was $2.378 billion and net income attributable to Royalty Pharma was $770.9 million. Q1 2026 Portfolio Receipts grew 10% to $925 million, operating cash flow grew 20% to $718 million, and full-year 2026 guidance was raised. | High |
| Valuation | At $58.43, verified trailing metrics were about 30.7x EPS, 12.9x operating cash flow per share, 3.8x book value, and a 1.61% dividend yield. The earnings multiple does not fully capture the non-cash accounting of royalty assets. | Medium |
| Technical trend | The July 31 snapshot placed RPRX above its 50-day and 200-day moving averages, with RSI around 55.21 after the stock reached a $60.44 52-week high in late July. That supports the trend but means the setup needs live-chart confirmation after a strong run. | Medium |
| Risk level | Risk is medium-high because patent erosion, generic competition, product concentration, impairment, clinical and regulatory outcomes, interest expense, leverage covenants, currency, and new-deal pricing can reduce value. | High |
| AI confidence | Reported facts and calculations are well documented. AI cannot know future drug sales, patent outcomes, royalty-asset values, deal flow, or the market multiple, and Q2 2026 results arrive after this page cutoff. | High data confidence |
| Investment certainty | The business model is easier to understand than early-stage biotech, but certainty remains medium because the current valuation needs continued portfolio growth and prudent capital allocation. | Medium |
RPRX AI stock forecast
The RPRX AI stock forecast uses a three-year scenario framework, not a promise. A local financial-rigor calculation using $1.90 EPS, 12%, 6%, and negative 3% growth assumptions, and 30x, 24x, and 16x target multiples produced reference values near $80.10, $54.30, and $27.70. Nine analysts carried a Buy consensus with a $59.89 average target at the cutoff.
$75 to $85
More likely if Tremfya, Voranigo, Evrysdi, and the cystic fibrosis franchise keep growing, new royalty and R&D co-funding deals such as JNJ-4804, TEV-408, and cliramitug meet underwriting returns, development-stage assets advance, interest costs remain controlled, and investors sustain a premium multiple for recurring portfolio cash flow.
$50 to $58
More likely if Portfolio Receipts grow at a mid-single-digit to high-single-digit rate, offsets from new assets balance mature-product declines such as Promacta and Imbruvica, leverage remains manageable, and valuation stays near the current range.
$24 to $32
More likely if major assets face faster generic or competitive erosion, royalty-asset assumptions are impaired as with Tazverik, deal pricing compresses returns, debt costs rise, or the market values the portfolio at a lower earnings multiple.
RPRX AI technical analysis
RPRX AI technical analysis uses the July 31, 2026 close of $58.43 and dated third-party statistics. This static page does not request live prices. The price was above both the 50-day and 200-day moving averages, while RSI around 55.21 suggested positive but moderated momentum after the stock made a $60.44 52-week high in late July.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $58.43 | Latest static closing price retrieved for this page, dated July 31, 2026. |
| Near support | $56.11 | The 50-day moving average from the dated StockAnalysis snapshot. |
| Secondary support | $46.44 | The 200-day moving average from the same dated snapshot. |
| Near resistance | $60.44 | The 52-week high reported by StockAnalysis and Macrotrends around the cutoff. Confirm on a live chart. |
| 50-day moving average | $56.11 | Price was above this average in the late-July technical snapshot. |
| 200-day moving average | $46.44 | Price was above this average in the late-July technical snapshot. |
| Momentum | RSI 55.21 | Positive momentum, but not a standalone buy or sell signal. |
| Volume | 2.71 million shares, 20-day average | A move through resistance carries more weight when live volume exceeds its recent average. |
| Volatility | 5-year beta 0.42 | Reported beta was below the market average, although drug, deal, and earnings news can still reprice the shares. |
| Invalidation | Sustained close below $56.11 | A confirmed loss of the 50-day average would weaken this short-term trend framework and call for a review of fundamentals and price action. |
RPRX AI trading strategy
The RPRX AI trading strategy is a research framework, not personalized advice. Pair live price and volume data with filings, product-level royalty trends, debt, capital deployment, and position-sizing rules that fit your own risk limit.
Review a breakout only if RPRX can hold above the $60.44 52-week-high area on stronger-than-average volume, while current Portfolio Receipts and key product updates remain constructive.
A failed breakout or sustained close below the 50-day average near $56.11 should invalidate the short-term setup before losses become open-ended.
If RPRX pulls back toward the 50-day average without a material change in royalty receipts, patent risk, debt, or deal underwriting, compare the valuation with updated cash generation and guidance.
Do not average down merely because the share price falls. Reassess if the decline follows a major product, impairment, leverage, or capital-allocation change.
Track Portfolio Receipts, exposure to the cystic fibrosis franchise and other large products, generic and patent events, new transaction terms such as the cliramitug deal, development-stage milestones, operating cash flow, debt, interest paid, repurchases, and dividends.
Refresh scenario ranges after the Q2 2026 results on August 5, 2026, after any material royalty transaction, after clinical or regulatory updates for key assets, or after any change in leverage and covenant coverage.
Investment research summary
Royalty Pharma turns capital and life-sciences underwriting into contractual claims on medicine sales. Customers and sellers use the platform when they value upfront funding or risk sharing more than waiting for future royalty cash flows.
The moat is built from relationships with innovators, a long transaction record, specialist due diligence, portfolio scale, and the ability to structure complex royalty and R&D co-funding agreements. It is not an absolute barrier to competing capital.
The thesis can fail if major drugs lose exclusivity faster than expected, generic competition or lower net pricing reduces sales, development assets fail, royalty forecasts are impaired as with Tazverik, debt service constrains flexibility, or new deals earn inadequate returns.
Management must allocate cash across royalty acquisitions, R&D co-funding, debt, dividends, and buybacks. The relevant scorecard is per-share cash-flow growth after accounting for the price paid, financing cost, asset duration, and downside protection.
Biopharma R&D requires large, patient capital pools, and royalty financing plus R&D co-funding can meet that need without operating commercial infrastructure. The long runway is real, but drug pricing, patent cliffs, concentration, clinical science, and capital-market competition shape returns.
At $58.43, the market reflects confidence in portfolio growth and capital deployment, while nine analysts average a $59.89 target. Margin of safety depends on the durability of therapy cash flows, conservative royalty-asset assumptions, a manageable debt burden, and purchasing new assets at attractive expected returns.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Price, market capitalization, and shares | $58.43 close on July 31, 2026, $33.65 billion market capitalization, and 575.83 million shares. financial_rigor.py market-cap math passed at 0.01% variance. | Macrotrends price history and StockAnalysis statistics | August 2, 2026 |
| FY2025 revenue | $2.378 billion, cross-validated between the SEC 10-K, Macrotrends, and StockAnalysis with all deviations below 0.1%. | Royalty Pharma 2025 Form 10-K, Macrotrends, and StockAnalysis | August 2, 2026 |
| FY2025 net income attributable to Royalty Pharma | $770.947 million, reported with FY2025 revenue in the full-year results release. | Royalty Pharma Q4 and FY2025 results | August 2, 2026 |
| FY2025 Portfolio Receipts and operating cash flow | $3.254 billion Portfolio Receipts, up 16%, and $2.490 billion net cash provided by operating activities. | Royalty Pharma Q4 and FY2025 results | August 2, 2026 |
| Q1 2026 operating update | $925 million Portfolio Receipts, up 10%, $887 million Royalty Receipts, up 13%, $718 million operating cash flow, up 20%, and $722 million Portfolio Cash Flow. Full-year 2026 guidance raised to $3,325 million to $3,450 million. | Royalty Pharma Q1 2026 results | August 2, 2026 |
| Q1 2026 balance sheet | $586 million cash and cash equivalents, $9.2 billion total debt principal value, $17.322 billion net financial royalty assets, and $9.937 billion total shareholders equity. | Royalty Pharma Q1 2026 results and StockAnalysis balance sheet | August 2, 2026 |
| Portfolio concentration and product drivers | The cystic fibrosis franchise contributed $253 million of Q1 2026 Portfolio Receipts. Tremfya, Voranigo, and Evrysdi helped growth, while Promacta declined with U.S. generic competition. Royalty Pharma recorded $69 million of non-cash impairment charges on Tazverik. | Royalty Pharma Q1 2026 results | August 2, 2026 |
| July 2026 transactions and corporate events | On July 22, 2026, Royalty Pharma agreed to acquire a portion of Neurimmune royalty interest in AstraZeneca cliramitug for up to $425 million including $125 million upfront. A Q3 2026 dividend of $0.235 per Class A share was declared on July 17, 2026. Q2 2026 results are scheduled for August 5, 2026. | Royalty Pharma news releases and GlobeNewswire | August 2, 2026 |
| Technical snapshot | 50-day moving average $56.11, 200-day moving average $46.44, RSI 55.21, 20-day average volume 2.71 million shares, five-year beta 0.42, and a $60.44 52-week high. | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus and valuation | Nine analysts held a Buy consensus with a $59.89 average 12-month price target at the cutoff. Trailing PE was about 30.7x with a forward PE of 11.37x and a 1.61% dividend yield. | StockAnalysis forecast and statistics | August 2, 2026 |
| Financial-rigor verification | Market-cap math passed at 0.01% variance; FY2025 revenue cross-validation passed with all sources within 0.1%; valuation and three-scenario calculations were run locally. | Pineify tools/financial_rigor.py local run | August 2, 2026 |
This RPRX AI stock analysis page is an informational tool only. It is not investment advice, a solicitation, or a guarantee of returns. Forecast ranges are scenarios based on available public data as of August 2, 2026 and can be wrong if drug sales, patent protection, generic competition, clinical outcomes, royalty-asset assumptions, debt costs, transaction returns, valuation multiples, or market conditions change. Q2 2026 results are scheduled for August 5, 2026, after this cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
